orthospinenews.com /5 days ago

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…

Read source
orthotw.com /1 week ago

NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury

Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study.

Read source
orthotw.com /1 month ago

Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Ra...

Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic -- Clinical data expected in 1H 202...

Read source
cafepharma.com /6 days ago

Axonics

Axonics Anonymous (not verified) Mon, 11/16/2026 - 00:40 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...

Read source
investing.com /1 month ago

Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...

Read source
seekingalpha.com /2 weeks ago

Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
orthotw.com /1 week ago

Axogen Shows Its Nerve as Sales Climb 26 Percent

Axogen’s 26% sales jump is great, but will acquiring BioCircuit make it even higher?

Read source
newswire.com /1 month ago

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~

Read source
biopharmadive.com /1 month ago

Parkinson’s cell therapy developer files to go public

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.

Read source
biopharmadive.com /1 month ago

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

Read source
prweb.com /1 week ago

Neuvivo appoints Michael McGrath MD, PhD as Chief Executive Officer

Appointment follows 12-month interim tenure of scientific, regulatory and commercial achievements for Phase 3 trial preparation in ALS PALO ALTO, Calif., Nov. 13, 2026 /PRNewswire-...

Read source
cafepharma.com /3 weeks ago

Geron

Geron Anonymous (not verified) Wed, 10/28/2026 - 16:21 field_thread_url https://cafepharma.com/boards/threads/geron.694511/ board name...

Read source
newswire.com /1 month ago

NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair Regeneration Technolo...

Capitalizing on a Global Hair Restoration Market Projected to Exceed $23 Billion, the Venture Integrates Advanced Exosome Delivery to Eliminate Microneedling and Reactivate Follicl...

Read source
seekingalpha.com /1 week ago

PepGen Inc. (PEPG) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results - Slideshow

Read source
orthotw.com /1 month ago

Consano Bio to Highlight C-1101, Its Potential First-in-Class Disease-Modifying Therapeutic for Chronic Sciatica, at Upc...

Read source
orthotw.com /1 month ago

Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Assoc...

Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the publication of a milestone study.

Read source
asia.nikkei.com /3 weeks ago

Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort

Read source
cafepharma.com /1 month ago

1,000,000,000 Billion Dollar Nemluvio Goal

1,000,000,000 Billion Dollar Nemluvio Goal Anonymous (not verified) Mon, 10/05/2026 - 04:07 field_thread_url https://cafepharma.com/boards/threads/1-000-0...

Read source
genengnews.com /1 month ago

Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial

A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies for Alzheimer's disease and was well tolerated in a Ph...

Read source
cafepharma.com /1 month ago

1,000,000,000 Billion Dollar Nemluvio Goal

1,000,000,000 Billion Dollar Nemluvio Goal Anonymous (not verified) Tue, 10/06/2026 - 04:08 field_thread_url https://cafepharma.com/boards/threads/1-000-0...

Read source
cafepharma.com /6 days ago

Vera Therapeutics

Vera Therapeutics Anonymous (not verified) Mon, 11/16/2026 - 00:40 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.